Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.0 million shares were traded.
Ratios:
For a better understanding of TCRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.55. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.44.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 16, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On May 13, 2024, Needham started tracking the stock assigning a Buy rating and target price of $11.
On June 22, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.Wedbush initiated its Outperform rating on June 22, 2023, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’24 when Lynx1 Capital Management LP bought 100,000 shares for $2.90 per share. The transaction valued at 290,140 led to the insider holds 5,357,347 shares of the business.
Lynx1 Capital Management LP bought 31,800 shares of TCRX for $95,629 on Dec 12 ’24. The 10% Owner now owns 5,257,347 shares after completing the transaction at $3.01 per share. On Nov 15 ’24, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 947 shares for $4.34 each. As a result, the insider paid 4,114 and bolstered with 5,225,547 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 15.88 while its Price-to-Book (P/B) ratio in mrq is 0.33.
Stock Price History:
Over the past 52 weeks, TCRX has reached a high of $9.69, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is -14.58%, while the 200-Day Moving Average is calculated to be -64.85%.
Shares Statistics:
A total of 52.31M shares are outstanding, with a floating share count of 43.27M. Insiders hold about 23.54% of the company’s shares, while institutions hold 66.82% stake in the company.
Earnings Estimates
A comprehensive evaluation of Tscan Therapeutics Inc (TCRX) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.22 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$0.85 and -$2.13 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$1.16, with 6.0 analysts recommending between -$0.78 and -$1.73.
Revenue Estimates
5 analysts predict $1.3M in revenue for the current quarter. It ranges from a high estimate of $2.5M to a low estimate of $500k. As of the current estimate, Tscan Therapeutics Inc’s year-ago sales were $536kFor the next quarter, 5 analysts are estimating revenue of $1.3M. There is a high estimate of $2.5M for the next quarter, whereas the lowest estimate is $500k.
A total of 5 analysts have provided revenue estimates for TCRX’s current fiscal year. The highest revenue estimate was $9.67M, while the lowest revenue estimate was $3.7M, resulting in an average revenue estimate of $5.88M. In the same quarter a year ago, actual revenue was $2.82M
